Motif Bio Share Discussion Threads

[scottdavid70] 03/12/2020 07:14

57 days since the term sheets were agreed -

‘all bases covered’ Graham Lumsden May 2019

So comforting and reassuring those words aren’t they otherwise you think there might not be a deal with his assurance. So far Graham has yet to be wrong...

[scottdavid70] 02/12/2020 07:57

Had to send this to Walbrook yesterday but no reply as I would like to see how as a PR agency you would spin this into justifying Lumsdens BONUS?

Iclaprim didn’t happen as predicted

No clinical trials post CRL - just the Phase iii for new trial

Route to market for Iclaprim- still hasn’t happened

In the market for new antibiotics- didn’t materialise

HABP trails - cancelled

EMA submission- pulled

Lamellar tie up news within months - still no news

Nasdaq IPO - two go’s - zero upside only extra regulation costs - delist

US Army trials - no news so therefore as of now no benefit

So explain how this even remotely

A) Keeps you in a job
B) puts you in line for a BONUS

Nothing as yet. When you read this it probably will take a few days to come up with some imaginative prose to counter the narrative

[scottdavid70] 02/12/2020 07:44

With the Pfizer vaccine now about to be ruled these Covid therapeutics must be redundant before they were even essential.

God speed to the BOD as it’s the only speed they know

[scottdavid70] 02/12/2020 07:19

Day 55 since term sheets agreed for the mushrooms

This is the chapter literally called Fed like Mushrooms

Before the final one which is

A Grand for Graham

as last man out to turn off the lights he deserves more money for his usefulness from start to finish

[jibba jabber] 01/12/2020 18:42

Yeah sorry to say for holders i can't see anyt5hing coming of this, what a disgrace of a management team. Really they ought to be scrutinised in a court of law, seems to me that they have lied their way through this whole debacle.

[scottdavid70] 01/12/2020 09:12

Have sent that as an alternative LinkedIn resume for Graham but as yet haven’t seen it supersede his current one

[scottdavid70] 01/12/2020 08:34

BONUS?

Iclaprim didn’t happen as predicted

No clinical trials post CRL - just the Phase iii for new trial

Route to market for Iclaprim- still hasn’t happened

In the market for new antibiotics- didn’t materialise

HABP trails - cancelled

EMA submission- pulled

Lamellar tie up news within months - still no news

Nasdaq IPO - two go’s - zero upside only extra regulation costs - delist

US Army trials - no news so therefore as of now no benefit

So explain how this even remotely

A) Keeps you in a job
B) puts you in line for a BONUS

[scottdavid70] 01/12/2020 08:17

Apart from the lack of speed it’s the utter disdain for shareholders who have supported the company. Easy to trot out a few sentences saying they appreciate the support but then their actions shown them up for what they are.

The shares aren’t traceable. They won’t even confirm what the patents mean potentially for investors.

If the several companies they say were at term sheet stage, does that mean term sheets HAVE reached or HAD reached

But the biggest one for me as everyone knows is the BONUS. WTF is that for? It’s is beyond comprehension that Lumsden is in line for a BONUS. The character of the BOD is shot to pieces with that staying in play.

Investors nursing losses of over 95% and he is getting a BONUS??

He didn’t even do his job of getting Iclaprim approved but is supposedly getting something called a BONUS for I assume doing something better that he actually failed to do!!! Please explain

[scottdavid70] 01/12/2020 07:29

Do you think Lumsden will put on his LinkedIn page at the end of January as another of the many ‘successesR17; he has had at Motif this:

I quietly and efficiently got Kotif de-listed from both the Nasdaq and AIM markets a mere 2 years after receiving a CRL from the FDA?

[scottdavid70] 01/12/2020 07:29

Do you think Lumsden will put on his LinkedIn page at the end of January as another of the many ‘successesR17; he has had at Motif this:

I quietly and efficiently got Kotif de-listed from both the Nasdaq and AIM markets a mere 2 years after receiving a CRL from the FDA?

[scottdavid70] 01/12/2020 05:41

2 new Iclaprim patents were granted to Sandoz in August 2020

Anyone know anything in terms of what it’s for with regard to Iclaprim and the potential upside for shareholders or as they call them in the Uranium office ‘mushroomsR17;?

Kept in the dark or led down a dead end. Feel vaguely familiar?

[smcl] 30/11/2020 20:41

We know We know!!!!!!!!!!

[scottdavid70] 30/11/2020 19:57

Only shareholders have lost

Not Lumsden

Not Walbrook PR

Not Peel Hunt (for the 709th time)

These have seen significant gains whilst shareholders have been obliterated

[scottdavid70] 30/11/2020 19:56

54 days since term sheet agreements.

Are they still in force?

Has the usual 30 day exclusivity run out that they usually have?

Are there still several companies involved or one?

Or none?

No one knows because the BOD don’t care about the shareholders whose holdings are shredded due to their failures.

[scottdavid70] 30/11/2020 17:59

We didn’t acquire any antibiotics that Leader Lumsden said we would either...

Can you tell me what he achieved because every time I look at his LinkedIn profile it says he achieved so much in his tenure yet the share price was 0.5p before it was suspended and nobody can trade their shares. What is the success he talks of so gushingly on LinkedIn?

[smcl] 30/11/2020 17:51

Ah shut up you fcsfing looney with your constant posts.

See a Psychiatrist.... and very soon is my advice.

[scottdavid70] 30/11/2020 17:50

32 times hey? Lots of interest surely in this blockbuster drug but strangely the sound of crickets is all that can be heard from Temple Chamber seeping onto Temple Avenue...

[scottdavid70] 30/11/2020 17:48

How’s e listeria project going with US State fund backing it?

Remember this nugget 32 time more potent there or thereabouts

“ will be utilising NIAID’s1 suite of preclinical services through JMI Laboratories to evaluate iclaprim against Listeria monocytogenes, a Gram-positive bacteria causing food-borne, life-threatening infections. The study, to be funded by NIAID, follows earlier in vitro testing in which iclaprim was ≥32-fold more potent than standard-of-care ampicillin and demonstrated consistent extracellular as well as intracellular activity against L. monocytogenes2.̶1;

The FDA said there was liver issues needing overcoming but then the US stumped up the cash for this trial.

Bizarre

[scottdavid70] 30/11/2020 17:43

How’s the Lamellar data with Motifs Iclaprim looking that was due a few months post May 2019?

More contact with aliens in the past year and 6 months

[scottdavid70] 30/11/2020 17:42

Any news on the US Army trials that were so significant they were worthy of a RNS One Year and one month plus ago?

[scottdavid70] 30/11/2020 10:55

Zero communication and zero empathy for the shareholders or recognition of what they have said and what has transpired gains you zero loyalty or respect in return

[scottdavid70] 30/11/2020 10:53

Like I have said they the management who have previous form and treat shareholders with utter disdain will keep them fed like mushrooms.

In my opinion as I have said when there is too little time to do anything else will present a plan that is a carve up for them despite the fact they have failed which is why shareholders have lost out so heavily but they haven’t. They will say this is the best plan we could get and you either get something (they win the biggest) or shareholders get nothing.

I will vote for nothing and I genuinely feel the group I chat too all feel the same way. To see them prosper while they have taken the company into the abyss off the back of everything they have promised and projected sticks forever in the throat

[scottdavid70] 30/11/2020 08:11

Lamellar and Motif are the same:

Remember how Motif were going to give an update a few months after the tie up with Lamellar?



You can see just after 2 mins where Lord Lumsden says it. This is in May 2019 by the way

Email Lamellar and ask where they are with this statement from 6th June this year

“ As such, it is ready to go to the clinic in COVID-19 as soon as a necessary quantity of GMP-grade material has been manufactured - i.e. within the current calendar year”

And you get nothing

See the similarities?